

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Therapeutics for people with COVID-19 [ID4038]

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (tixagevimab and cilgavimab) • Eli and Lilly (baricitinib) • Gilead Sciences (remdesivir) • GlaxoSmithKline (sotrovimab) • Merck Sharp & Dohme (molnupiravir) • Pfizer (nirmatrelvir and ritonavir) • Roche (casirivimab, imdevimab and tocilizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Pulmonary Fibrosis • Anthony Nolan • Blood Cancer UK • covid:aid • Diabetes UK • Down's Syndrome Association • Immunodeficiency UK • Kidney Care UK • Leukaemia Care • Long Covid Kids • Long COVID SOS • Long Covid Support • Lupus UK • Lymphoma Action • MS Society • Multiple Sclerosis Trust • Myeloma UK • Sarcoidosis UK • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Infection Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Kidney Research UK • Long Covid Research Initiative <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Faculty of Public Health Medicine • Public Health Wales • Royal Society for Public Health • UK Health Security Agency

Final Stakeholder list for the Multiple Technology Appraisal of therapeutics for people with COVID-19 [ID4038]

Issue date: August 2022.

© National Institute for Health and Care Excellence 2022. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Society for Allergy & Clinical Immunology • British Society for Immunology • British Thoracic Society • British Transplant Society • Cancer Research UK • Faculty of Pharmaceutical Medicine • Royal College of Physicians • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Draft Guidance..

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Draft Guidance.

Commentators

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the Final Draft Guidance for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.